AURKB and pancreatic neoplasm: CAM2602 acts by a novel mechanism compared to ATP-competitiveinhibitors and is highly specific to Aurora A over Aurora B. Consistentwith our finding that Aurora A overexpression drives taxane resistance,these inhibitors synergize with paclitaxel to suppress the outgrowthof pancreatic cancer cells.